Company intelligence / Profile preview
Consano Bio
Burlington, MA, United Statesconsanobio.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Submitted IND (CBER) for treatment of chronic Lumbosacral Radiculopathy. Demonstrated preclinical evidence for reparative anti-inflammatory and growth factor activity that drives cellular healing and repair. In a model of neuropathic pain, showed significant recovery of nerve function. First patient dosing in Phase I study expected in Q3 2025.
- Therapeutic areas
- Neurology
- Modalities
- Biologic therapeuticAllogenic Multi-Protein Therapeutic (AMPT)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Consano Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Consano Bio.